1. Home
  2. AMPH vs GERN Comparison

AMPH vs GERN Comparison

Compare AMPH & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amphastar Pharmaceuticals Inc.

AMPH

Amphastar Pharmaceuticals Inc.

HOLD

Current Price

$18.18

Market Cap

971.8M

Sector

Health Care

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.26

Market Cap

821.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMPH
GERN
Founded
1996
1990
Country
United States
United States
Employees
N/A
258
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
971.8M
821.1M
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
AMPH
GERN
Price
$18.18
$1.26
Analyst Decision
Buy
Hold
Analyst Count
8
3
Target Price
$28.38
$2.17
AVG Volume (30 Days)
644.5K
14.2M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.14
N/A
Revenue
$719,887,000.00
N/A
Revenue This Year
$6.90
$26.91
Revenue Next Year
$4.64
$43.75
P/E Ratio
$130.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.65
$1.04
52 Week High
$31.26
$2.01

Technical Indicators

Market Signals
Indicator
AMPH
GERN
Relative Strength Index (RSI) 40.00 32.94
Support Level $17.03 $1.24
Resistance Level $20.08 $1.29
Average True Range (ATR) 0.81 0.09
MACD -0.21 -0.02
Stochastic Oscillator 19.16 10.42

Price Performance

Historical Comparison
AMPH
GERN

About AMPH Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: